Janina Stępińska

Janina Stępińska

Auto-generated profile, based on publicly available information

Janina Stępińska

Institute of Cardiology, Warsaw, Poland

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2024 in Archives of Medical Science
Verified
Journal Article
Closed access
BSBOZENA SOSNOWSKA
BOZENA SOSNOWSKA
JSJanina Stepinska
Janina Stepinska
PMPrzemysław Mitkowski
Przemysław Mitkowski
Agata Bielecka-DabrowaAgata Bielecka-Dabrowa
Agata Bielecka-Dabrowa
BBBeata Bobrowska
Beata Bobrowska
Maciej BanachMaciej Banach
Maciej Banach
Lipoprotein(a) [Lp(a)] is made up of a low-density lipoprotein (LDL) particle and a specific apolipoprotein(a). The blood concentration of Lp(a) is approximately 90% genetically determined, and the main genetic factor determining Lp(a) levels is the size of the apo(a) isoform, which is determined by the number of KIV2 domain repeats. The size of the apo(a) isoform is inversely proportional to the blood concentration of Lp(a). Lp(a) is a strong and independent cardiovascular risk factor. Elevated Lp(a) levels ≥ 50 mg/dl (≥ 125 nmol/l) are estimated to occur in more than 1.5 billion people worldwide. However, determination of Lp(a) levels is performed far too rarely, including Poland, where, in fact, it is only since the 2021 guidelines of the Polish Lipid Association (PoLA) and five other scientific societies that Lp(a) measurements have begun to be performed. Determination of Lp(a) concentrations is not easy due to, among other things, the different sizes of the apo(a) isoforms; however, the currently available certified tests make it possible to distinguish between people with low and high cardiovascular risk with a high degree of precision. In 2022, the first guidelines for the management of patients with elevated lipoprotein(a) levels were published by the European Atherosclerosis Society (EAS) and the American Heart Association (AHA). The first Polish guidelines are the result of the work of experts from the two scientific societies and their aim is to provide clear, practical recommendations for the determination and management of elevated Lp(a) levels.

1 October 2017 in The American Journal of Cardiology
Verified
Journal Article
Open access
TJToni Jäntti
Toni Jäntti
TTTuukka Tarvasmäki
Tuukka Tarvasmäki
VHVeli-Pekka Harjola
Veli-Pekka Harjola
John ParissisJohn Parissis
John Parissis
KPKari Pulkki
Kari Pulkki
PGPiotr Góral
Piotr Góral
Cardiogenic shock (CS) is a cardiac emergency often leading to multiple organ failure and death. Assessing organ dysfunction and appropriate risk stratification are central for the optimal management of these patients. The purpose of this study was to assess the prevalence of abnormal liver function tests (LFTs), as well as early changes of LFTs and their impact on outcome in CS. We measured LFTs in 178 patients in CS from serial blood samples taken at 0 hours, 12 hours, and 24 hours. The associations of LFT abnormalities and their early changes with all-cause 90-day mortality were estimated using Fisher's exact test and Cox proportional hazards regression analysis. Baseline alanine aminotransferase (ALT) was abnormal in 58% of the patients, more frequently in nonsurvivors. Abnormalities in other LFTs analyzed (alkaline phosphatase, gamma-glutamyl transferase, and total bilirubin) were not associated with short-term mortality. An increase in ALT of >20% within 24 hours (ΔALT>+20%) was observed in 24% of patients. ΔALT>+20% was associated with a more than 2-fold increase in mortality compared with those with stable or decreasing ALT (70% and 28%, p +20% was associated with increased 90-day mortality independent of other known risk factors. In conclusion, an increase in ALT in the initial phase was seen in 1/4 of patients in CS and was independently associated with 90-day mortality. This finding suggests that serial ALT measurements should be incorporated in the clinical assessment of patients in CS.

31 January 2024 in Global Heart
Verified
Journal Article
Open access
PDF file
EDE. Ulysses Dorotheo
E. Ulysses Dorotheo
MAMonika Arora
Monika Arora
ABAmitava Banerjee
Amitava Banerjee
EBEduardo Bianco
Eduardo Bianco
NCNuan Ping Cheah
Nuan Ping Cheah
YWYunshu Wang
Yunshu Wang
Nicotine is universally recognized as the primary addictive substance fuelling the continued use of tobacco products, which are responsible for over 8 million deaths annually. In recent years, the popularity of newer recreational nicotine products has surged drastically in many countries, raising health and safety concerns. For decades, the tobacco industry has promoted the myth that nicotine is as harmless as caffeine. Nonetheless, evidence shows that nicotine is far from innocuous, even on its own. In fact, numerous studies have demonstrated that nicotine can harm multiple organs, including the respiratory and cardiovascular systems. Tobacco and recreational nicotine products are commercialized in various types and forms, delivering varying levels of nicotine along with other toxic compounds. These products deliver nicotine in profiles that can initiate and perpetuate addiction, especially in young populations. Notably, some electronic nicotine delivery systems (ENDS) and heated tobacco products (HTP) can deliver concentrations of nicotine that are comparable to those of traditional cigarettes. Despite being regularly advertised as such, ENDS and HTP have demonstrated limited effectiveness as tobacco cessation aids in real-world settings. Furthermore, ENDS have also been associated with an increased risk of cardiovascular disease. In contrast, nicotine replacement therapies (NRT) are proven to be safe and effective medications for tobacco cessation. NRTs are designed to release nicotine in a slow and controlled manner, thereby minimizing the potential for abuse. Moreover, the long-term safety of NRTs has been extensively studied and documented. The vast majority of tobacco and nicotine products available in the market currently contain nicotine derived from tobacco leaves. However, advancements in the chemical synthesis of nicotine have introduced an economically viable alternative source. The tobacco industry has been exploiting synthetic nicotine to circumvent existing tobacco control laws and regulations. The emergence of newer tobacco and recreational nicotine products, along with synthetic nicotine, pose a tangible threat to established tobacco control policies. Nicotine regulations need to be responsive to address these evolving challenges. As such, governments should regulate all tobacco and non-medical nicotine products through a global, comprehensive, and consistent approach in order to safeguard tobacco control progress in past decades.

12 July 2018 in American Journal of Case Reports
Verified
Journal Article
Open access
PDF file
KKKarolina Kryczka
Karolina Kryczka
ZDZofia Dzielińska
Zofia Dzielińska
MFMaria Franaszczyk
Maria Franaszczyk
IWIzabela Wojtkowska
Izabela Wojtkowska
JHJan Henzel
Jan Henzel
MDMarcin Demkow
Marcin Demkow
BACKGROUND:Peripartum cardiomyopathy (PPCM) is a potentially life-threatening, pregnancy-associated cause of heart failure affecting previously healthy women. Recent research suggests a possible role of 16-kDa prolactin in promoting cardiomyocyte dam...

1 April 2021 in Chest
Verified
Journal Article
Open access
MZMichel Zeitouni
Michel Zeitouni
IAIbrahim Akin
Ibrahim Akin
SDSteffen Desch
Steffen Desch
OBOlivier Barthélémy
Olivier Barthélémy
DBDelphine Brugier
Delphine Brugier
HMHauguel- Moreau
Hauguel- Moreau
The impact of ECG presentations of acute myocardial infarction (AMI) in cardiogenic shock is unknown. In myocardial infarction with cardiogenic shock, is there a difference in the outcomes and effect of revascularization strategies between non-ST-segment elevation myocardial infarction (NSTE-MI) and left bundle branch block (LBBB-MI) versus STEMI? Cardiogenic shock patients from the CULPRIT-SHOCK trial presenting with NSTE-MI or LBBB-MI were compared with STE-MI patients for 30-day and 1-year all-cause mortality. The interaction between ECG presentation and the effect of revascularization strategies on outcomes was evaluated. Of 665 cardiogenic shock patients analyzed, 55.9% presented with STE-MI, 29.3% with NSTE-MI and 14.7% with LBBB-MI. Patients differed in age (68.0 years in STE-MI, 71.0 years in NSTE-MI and 73.5 years in LBBB-MI, p=0.015), cardiovascular risk factors and angiographic severity. There was no difference in the 30-day risk of death between NSTE-MI and STE-MI (48.7 % vs. 43.0%, aOR 1.05, 95%CI, 0.66 - 1.67, p=0.85), nor between LBBB-MI and STE-MI (59.2% vs. 43.0%, aOR 1.31, 95%CI 0.73 - 2.34, p=0.36). While the univariate risk of 1-year death was higher in NSTE-MI and LBBB-MI patients compared with STE-MI, ECG presentation was not an independent risk factor of mortality after adjustment (NSTE-MI vs. STE-MI : 56.4 % vs 46.8 % aOR 1.21, 95%CI 0.76 - 1.92, p=0.42 ; LBBB-MI vs. STEMI : 69.4% vs. 46.8% : aOR : 1.59, 95%CI 0.89 - 2.84, p=0.12) . ECG presentation did not modify the effect of the revascularization strategy on 30-day and 1-year mortality (p interaction =0.91 and 0.97). In patients with cardiogenic shock, NSTE-MI and LBBB-MI presentations reflect higher risk profiles than STE-MI but are not independent risk factors of mortality. ECG presentations did not modify the treatment effect, supporting culprit-lesion-only PCI as the preferred strategy across the AMI spectrum.

2 January 2013 in Cardiology Journal
Verified
Journal Article
Open access
PDF file
PTPaweł Tyczyński
Paweł Tyczyński
KKKrzysztof Kukuła
Krzysztof Kukuła
APArkadiusz Pietrasik
Arkadiusz Pietrasik
TBTomasz Bochenek
Tomasz Bochenek
ADArtur Dębski
Artur Dębski
AWAdam Witkowski
Adam Witkowski
Background: The aim of the study was to describe a series of acute coronary syndrome (ACS) patients in whom anomalous origin of culprit coronary artery (AOCCA) was diagnosed. Percutaneous coronary interventions (PCI) in AOCCA are performed very infrequently. Methods: Electronic databases from three high-volume tertiary cardiac centers were retrospectively searched for the presence of AOCCA in ACS. Results: Different types of AOCCA in ACS were identified in 20 patients. The most frequent AOCCA was left circumflex coronary artery (LCx) originating from right coronary artery (RCA) or directly from the right coronary sinus (RCS), n = 13, followed by high/atypical RCA, n = 3, left coronary artery (LCA) originating from RCS (n = 3) with either RCA-AOCCA (n = 1) or left anterior descending coronary artery (LAD)-AOCCA (n = 1) or RCA originating from left sinus of Valsalva, (n = 1), LAD originating from RCA (n = 1). In 1 ST-segment elevation myocardial infarction (STEMI)-patient RCA-AOCCA cannulation was unsuccessful, in 1 non-STEMI-patient AOCCA was missed, 1 ACS- -patient was treated surgically and 1 ACS-patient was treated conservatively (both patients with non- STEMI). In the remaining patients PCI was successfully performed. Conclusions: The most frequently encountered AOCCA is LCx branching-off from RCA. AOCCA may either be difficult to cannulate and PCI aborted even in STEMI, or missed, especially when the intermediate branch from LCA is mimicking proper LCx. Background: The aim of the study was to describe a series of acute coronary syndrome (ACS) patients in whom anomalous origin of culprit coronary artery (AOCCA) was diagnosed. Percutaneous coronary interventions (PCI) in AOCCA are performed very infrequently. Methods: Electronic databases from three high-volume tertiary cardiac centers were retrospectively searched for the presence of AOCCA in ACS. Results: Different types of AOCCA in ACS were identified in 20 patients. The most frequent AOCCA was left circumflex coronary artery (LCx) originating from right coronary artery (RCA) or directly from the right coronary sinus (RCS), n = 13, followed by high/atypical RCA, n = 3, left coronary artery (LCA) originating from RCS (n = 3) with either RCA-AOCCA (n = 1) or left anterior descending coronary artery (LAD)-AOCCA (n = 1) or RCA originating from left sinus of Valsalva, (n = 1), LAD originating from RCA (n = 1). In 1 ST-segment elevation myocardial infarction (STEMI)-patient RCA-AOCCA cannulation was unsuccessful, in 1 non-STEMI-patient AOCCA was missed, 1 ACS- -patient was treated surgically and 1 ACS-patient was treated conservatively (both patients with non- STEMI). In the remaining patients PCI was successfully performed. Conclusions: The most frequently encountered AOCCA is LCx branching-off from RCA. AOCCA may either be difficult to cannulate and PCI aborted even in STEMI, or missed, especially when the intermediate branch from LCA is mimicking proper LCx.